ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Audio By Carbonatix

AUSTIN, Texas--(BUSINESS WIRE)--Sep 2, 2025--

ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8 th through September 10 th, 2025.

Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Event Details:

• Conference: 27th Annual H.C. Wainwright Global Investment Conference

• Date: September 8-10th, 2025

Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email [email protected]

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies—such as its LENS ai ™ platform—to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research.

For more information, visit www.ipatherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250902352942/en/

CONTACT: Investor Contact

Louie Toma, CPA, CFA

Managing Director, CoreIR

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CANADA TEXAS

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: ImmunoPrecise Antibodies Ltd.

Copyright Business Wire 2025.

PUB: 09/02/2025 08:01 AM/DISC: 09/02/2025 08:03 AM

http://www.businesswire.com/news/home/20250902352942/en